Newron Pharmaceuticals S.p.A. (FRA:NP5)

Germany flag Germany · Delayed Price · Currency is EUR
14.88
+0.64 (4.49%)
At close: Oct 20, 2025
4.49%
Market Cap310.20M
Revenue (ttm)59.88M
Net Income (ttm)25.33M
Shares Outn/a
EPS (ttm)1.19
PE Ratio12.25
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume12,785
Average Volume1,966
Open14.60
Previous Close14.24
Day's Range14.52 - 15.26
52-Week Range5.91 - 17.18
Betan/a
RSI59.87
Earnings DateDec 18, 2025

About Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson’s in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company’s lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III cl... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 22
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol NP5
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.